Skip to main content
AmigoFish

Jefferies London 2026: Nuvation Bio Founder & CEO David Hung shares an update on the launch of IBTROZI (next-gen ROS1 inhibitor and follow-on pipeline projects

From BiotechTV - News · · 9 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

He discusses the launch and his thoughts on any future copetitors in the space. Plus an update on the mIDH1 inhibitor safusidenib, and a drug-drug interaction platform that was the basis for founding the company.

Back to BiotechTV - News · Report a problem